AbbVie enters obesity drug market with up to $2.2 billion Gubra deal
The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...
STAT50m
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
Pharmaceutical Technology39m
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...
Medscape11m
Rosacea: Newer Approaches to Diagnosis, Management
Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...
Hosted on MSN39m
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ...
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Three of the five top-performing Vanguard ETFs of 2025 so far share a key common denominator: They're all international funds ...